6.83
price up icon1.49%   0.10
after-market Handel nachbörslich: 6.83
loading
Schlusskurs vom Vortag:
$6.73
Offen:
$6.64
24-Stunden-Volumen:
1.01M
Relative Volume:
1.29
Marktkapitalisierung:
$368.68M
Einnahmen:
$2.81M
Nettoeinkommen (Verlust:
$-97.34M
KGV:
-4.3228
EPS:
-1.58
Netto-Cashflow:
$-91.47M
1W Leistung:
-12.55%
1M Leistung:
-0.15%
6M Leistung:
+72.47%
1J Leistung:
-24.20%
1-Tages-Spanne:
Value
$6.56
$7.12
1-Wochen-Bereich:
Value
$6.50
$8.50
52-Wochen-Spanne:
Value
$2.315
$10.13

Fulcrum Therapeutics Inc Stock (FULC) Company Profile

Name
Firmenname
Fulcrum Therapeutics Inc
Name
Telefon
617-651-8851
Name
Adresse
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Name
Mitarbeiter
45
Name
Twitter
@fulcrumtx
Name
Nächster Verdiensttermin
2024-11-05
Name
Neueste SEC-Einreichungen
Name
FULC's Discussions on Twitter

Vergleichen Sie FULC mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
FULC
Fulcrum Therapeutics Inc
6.83 363.28M 2.81M -97.34M -91.47M -1.58
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
462.13 117.32B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
558.87 58.89B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
401.80 51.14B 2.46B -319.09M -52.09M -2.47
Biotechnology icon
ARGX
Argen X Se Adr
673.80 41.02B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
299.01 32.59B 3.81B -644.79M -669.77M -6.24

Fulcrum Therapeutics Inc Stock (FULC) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-07-29 Hochstufung H.C. Wainwright Neutral → Buy
2025-05-23 Hochstufung Leerink Partners Market Perform → Outperform
2025-05-15 Hochstufung Cantor Fitzgerald Neutral → Overweight
2024-09-13 Herabstufung H.C. Wainwright Buy → Neutral
2024-09-12 Herabstufung BofA Securities Neutral → Underperform
2024-09-12 Herabstufung Cantor Fitzgerald Overweight → Neutral
2024-09-12 Herabstufung Leerink Partners Outperform → Market Perform
2024-09-12 Herabstufung RBC Capital Mkts Outperform → Sector Perform
2024-09-12 Herabstufung Stifel Buy → Hold
2024-09-09 Hochstufung BofA Securities Underperform → Neutral
2024-05-20 Eingeleitet Cantor Fitzgerald Overweight
2024-03-13 Eingeleitet RBC Capital Mkts Outperform
2023-09-25 Eingeleitet Goldman Neutral
2023-08-23 Hochstufung H.C. Wainwright Neutral → Buy
2023-08-22 Hochstufung Stifel Hold → Buy
2023-05-04 Herabstufung Goldman Buy → Neutral
2023-03-10 Herabstufung Credit Suisse Outperform → Neutral
2023-03-10 Herabstufung H.C. Wainwright Buy → Neutral
2023-03-09 Herabstufung Stifel Buy → Hold
2023-02-28 Herabstufung Morgan Stanley Overweight → Equal-Weight
2023-02-24 Herabstufung BofA Securities Neutral → Underperform
2022-11-15 Eingeleitet Goldman Buy
2022-03-08 Eingeleitet Oppenheimer Outperform
2022-03-03 Hochstufung BofA Securities Underperform → Neutral
2021-08-11 Hochstufung Morgan Stanley Equal-Weight → Overweight
2021-04-26 Fortgesetzt Credit Suisse Outperform
2021-03-22 Eingeleitet Credit Suisse Outperform
2021-03-02 Eingeleitet Stifel Buy
2020-10-16 Eingeleitet Piper Sandler Overweight
2020-08-12 Herabstufung BofA Securities Neutral → Underperform
2020-08-12 Bestätigt H.C. Wainwright Buy
2020-08-12 Herabstufung Morgan Stanley Overweight → Equal-Weight
2020-06-19 Herabstufung BofA/Merrill Buy → Neutral
2020-06-17 Eingeleitet BTIG Research Buy
2019-10-03 Eingeleitet H.C. Wainwright Buy
2019-08-12 Eingeleitet BofA/Merrill Buy
Alle ansehen

Fulcrum Therapeutics Inc Aktie (FULC) Neueste Nachrichten

pulisher
04:09 AM

Why is Fulcrum Therapeutics Inc. stock attracting strong analyst attentionMassive stock growth - jammulinksnews.com

04:09 AM
pulisher
02:10 AM

Is Fulcrum Therapeutics Inc. a good long term investmentTremendous portfolio expansion - jammulinksnews.com

02:10 AM
pulisher
01:07 AM

What is Fulcrum Therapeutics Inc. company’s growth strategyUnlock powerful market insights for success - jammulinksnews.com

01:07 AM
pulisher
12:24 PM

Fulcrum Therapeutics shares slide 17% after sickle cell trial results - MSN

12:24 PM
pulisher
10:04 AM

Technical signs of recovery in Fulcrum Therapeutics Inc.Price Spike Prediction for Active Traders - Newser

10:04 AM
pulisher
05:17 AM

Applying big data sentiment scoring on Fulcrum Therapeutics Inc.Entry Optimization Guide with Volume Analysis - Newser

05:17 AM
pulisher
Aug 02, 2025

When is Fulcrum Therapeutics Inc. stock expected to show significant growthFree Market Dynamics Reports - jammulinksnews.com

Aug 02, 2025
pulisher
Aug 02, 2025

How strong is Fulcrum Therapeutics Inc. company’s balance sheetMaximize returns with timely market signals - jammulinksnews.com

Aug 02, 2025
pulisher
Aug 02, 2025

How does Fulcrum Therapeutics Inc. generate profit in a changing economyHigh-profit capital plays - jammulinksnews.com

Aug 02, 2025
pulisher
Aug 02, 2025

What institutional investors are buying Fulcrum Therapeutics Inc. stockInvest smarter with cutting-edge analytics - jammulinksnews.com

Aug 02, 2025
pulisher
Aug 02, 2025

Is Fulcrum Therapeutics Inc. stock overvalued or undervaluedAccess exclusive market insights for free - jammulinksnews.com

Aug 02, 2025
pulisher
Aug 02, 2025

FY2025 EPS Estimates for FULC Raised by Cantor Fitzgerald - Defense World

Aug 02, 2025
pulisher
Aug 02, 2025

Does Fulcrum Therapeutics Inc. qualify in momentum factor screeningTrend Confirmation Scanner with Entry Focus - Newser

Aug 02, 2025
pulisher
Aug 02, 2025

Will Fulcrum Therapeutics Inc. Stock Benefit from AI and Green Energy TrendsOversold Opportunity Scanner with RSI Data - Newser

Aug 02, 2025
pulisher
Aug 02, 2025

Q3 Earnings Forecast for FULC Issued By Leerink Partnrs - Defense World

Aug 02, 2025
pulisher
Aug 02, 2025

Is Fulcrum Therapeutics Inc. stock ready for a breakoutReal-Time AI Entry Forecast Generator - Newser

Aug 02, 2025
pulisher
Aug 02, 2025

Is Fulcrum Therapeutics Inc. a Top Dividend Stock to Watch in 2025Free Portfolio Diversification Stock Ideas - Newser

Aug 02, 2025
pulisher
Aug 01, 2025

Are Bears Losing Grip on Fulcrum Therapeutics Inc.Reliable Investment Entry Signals Confirmed by Charts - metal.it

Aug 01, 2025
pulisher
Aug 01, 2025

What catalysts could drive Fulcrum Therapeutics Inc. stock higher in 2025Market Forecast Tracker For Smart Trading - jammulinksnews.com

Aug 01, 2025
pulisher
Aug 01, 2025

How to interpret RSI for Fulcrum Therapeutics Inc. stockTen-Year Sector Performance and Summary Analysis - Newser

Aug 01, 2025
pulisher
Jul 31, 2025

What is the risk reward ratio of investing in Fulcrum Therapeutics Inc. stockPre Market Insights For Beginners - jammulinksnews.com

Jul 31, 2025
pulisher
Jul 31, 2025

How many analysts rate Fulcrum Therapeutics Inc. as a “Buy”Wealth Building Picks That Work - jammulinksnews.com

Jul 31, 2025
pulisher
Jul 31, 2025

Fulcrum defended at H.C. Wainwright after data for sickle cell disease drug - MSN

Jul 31, 2025
pulisher
Jul 31, 2025

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives $6.29 Consensus Target Price from Brokerages - Defense World

Jul 31, 2025
pulisher
Jul 31, 2025

Key External Factors That Drive Fulcrum Therapeutics Inc. Stock Price MovementsAI Trading Suggestions With Accuracy Focus Released - metal.it

Jul 31, 2025
pulisher
Jul 30, 2025

Fulcrum Therapeutics stock price target raised to $5 at RBC Capital - Investing.com Canada

Jul 30, 2025
pulisher
Jul 30, 2025

Fulcrum Therapeutics (NASDAQ:FULC) Rating Increased to Buy at HC Wainwright - Defense World

Jul 30, 2025
pulisher
Jul 30, 2025

Is Fulcrum Therapeutics Inc. building a consolidation baseTrend Following Ideas with Volume Confirmation - Newser

Jul 30, 2025
pulisher
Jul 30, 2025

Published on: 2025-07-30 02:00:45 - Newser

Jul 30, 2025
pulisher
Jul 30, 2025

Fulcrum Therapeutics 2024 Q2 Earnings Strong Turnaround with Net Income Swing of 333% - AInvest

Jul 30, 2025
pulisher
Jul 29, 2025

H.C. Wainwright upgrades Fulcrum Therapeutics stock rating on promising SCD data - Investing.com Canada

Jul 29, 2025
pulisher
Jul 29, 2025

Buy Rating for Fulcrum Therapeutics: Promising Potential of Pociredir in Sickle Cell Disease Treatment - TipRanks

Jul 29, 2025
pulisher
Jul 29, 2025

HC Wainwright Raises Fulcrum Therapeutics' PT to $12 from $4 - AInvest

Jul 29, 2025
pulisher
Jul 29, 2025

Fulcrum Therapeutics Inc. Stock Fails to Break Resistance Traders ReactDaily Smart Money Movement Monitor Activated - beatles.ru

Jul 29, 2025
pulisher
Jul 29, 2025

Fulcrum Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView

Jul 29, 2025
pulisher
Jul 29, 2025

Fulcrum Therapeutics, Inc. SEC 10-Q Report - TradingView

Jul 29, 2025
pulisher
Jul 29, 2025

Whirlpool Posts Downbeat Earnings, Joins Harmonic, Stanley Black & Decker And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga

Jul 29, 2025
pulisher
Jul 29, 2025

Fulcrum Therapeutics Plunges 29.58% on PIONEER Trial Results - AInvest

Jul 29, 2025
pulisher
Jul 29, 2025

Fulcrum Therapeutics Inc. (FULC) Tops Q2 EPS by 1c - StreetInsider

Jul 29, 2025
pulisher
Jul 29, 2025

Fulcrum Therapeutics stock falls after sickle cell disease trial results By Investing.com - Investing.com Nigeria

Jul 29, 2025
pulisher
Jul 29, 2025

Fulcrum Therapeutics stock falls after sickle cell disease trial results - Investing.com

Jul 29, 2025
pulisher
Jul 29, 2025

Fulcrum Therapeutics Announces Results from the 12 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease - The Manila Times

Jul 29, 2025
pulisher
Jul 29, 2025

Fulcrum Therapeutics Reports Positive Results from Phase 1b PIONEER Trial of Pociredir for Sickle Cell Disease - Quiver Quantitative

Jul 29, 2025
pulisher
Jul 29, 2025

Fulcrum Therapeutics reports Q2 results, pociredir trial data - StreetInsider

Jul 29, 2025
pulisher
Jul 29, 2025

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2025 - Yahoo Finance

Jul 29, 2025
pulisher
Jul 29, 2025

Breakthrough Sickle Cell Treatment Achieves 44% Success Rate in Latest Clinical Trial Data - Stock Titan

Jul 29, 2025
pulisher
Jul 29, 2025

Why Fulcrum Therapeutics Inc. stock attracts strong analyst attentionDaily Investment Ideas with Market Insight - Newser

Jul 29, 2025
pulisher
Jul 29, 2025

Published on: 2025-07-29 13:21:15 - beatles.ru

Jul 29, 2025

Finanzdaten der Fulcrum Therapeutics Inc-Aktie (FULC)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$75.59
price up icon 0.93%
$37.11
price up icon 0.84%
$108.69
price up icon 1.31%
$27.07
price up icon 2.65%
$107.34
price down icon 0.15%
biotechnology ONC
$299.01
price down icon 0.70%
Kapitalisierung:     |  Volumen (24h):